• news.cision.com/
  • Scandion Oncology A/S/
  • Anti-bacterial treatment: Novel analogues with more than tenfold higher potency identified and technical issues with the in vivo experiments
English

Anti-bacterial treatment: Novel analogues with more than tenfold higher potency identified and technical issues with the in vivo experiments

Report this content

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has identified novel analogues with more than tenfold higher potency against antibiotic resistant bacteria and that the in vivo animal study has been delayed from Q4 2019 until Q1 2020 due to technical issues with the control substance. This will not affect the company's goal of finding a partner for commercializing Scandion Oncology’s drug candidate SOM-001 and analogs for antibiotic resistance in 2020. Moreover, it will not affect the company’s cash position.

Earlier this year Scandion Oncology announced positive preclinical results in antibiotic resistance. Scandion Oncology discovered that a number of the company’s compounds are able to overcome antibiotic resistance in bacterial infections through a different mechanism of action than the one related to reversing cancer resistance. Scandion Oncology have since the previous announcement (press release MAR 11, 2019) worked on extending the company’s insight and understanding of this interesting effect. During the process, Scandion Oncology has identified analogues with more than tenfold higher activity than the original compound and generated very interesting data on the mode of action of these compounds. In parallel to these activities, Scandion Oncology wanted to test the anti-microbial effects in animal models of serious human antibiotic resistant bacterial infections. However, due to technical issues with the control substance at the CRO, Scandion Oncology will restart the study at the CRO laboratory in January 2020 and the results will therefore not be available until late Q1, 2020. This will not affect the company's goal of finding a partner for commercializing SOM-001 and analogues in 2020.

For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on December 16, 2019.

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Scandion Oncology has reported that one of its compounds has significant anti-microbial effects on antibiotic resistant bacteria.

Subscribe